Elanco Animal Health Incorporated (ELAN) Market Cap & Valuation Ratios
Elanco Animal Health Incorporated (ELAN) has a market cap of $11.3B and a price-to-sales ratio of 2.2, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ELANElanco Animal Health IncorporatedFollow ELAN — free
—
Price chart with a free account
- Market cap
- 11.3B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 6 Nov, in 13 days
Peers
drug manufacturers - specialty & generic · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| ELAN | 11 | — | 2.9 | 27.8 | 3.4% | +12% | -3% | -2% |
| UTHR | 25 | 21.0 | 7.1 | 15.1 | 4.3% | +2% | 44% | 23% |
| VTRS | 21 | — | 2.2 | 12.2 | 9.5% | +4% | -0.6% | -0.3% |
| NBIX | 15 | 20.9 | 4.2 | 16.8 | 6.0% | +34% | 24% | 21% |
| ALKS | 7.3 | 114.8 | 4.9 | 45.6 | 3.0% | +11% | 7% | 3% |
| LNTH | 6.5 | 24.2 | 4.2 | 16.6 | 6.0% | +2% | 19% | 20% |
| AMRX | 6.5 | 41.6 | 2.9 | 14.0 | 1.3% | +9% | 15% | 17% |
| HIMS | 6.5 | — | 2.7 | — | 1.0% | +28% | -6% | -21% |
| KNSA | 6.0 | 78.3 | 6.5 | 53.5 | 3.1% | +59% | 12% | 18% |
| INDV | 4.1 | 12.4 | 3.3 | 10.1 | -2.7% | +13% | 32% | 667% |
| LQDA | 3.8 | 31.2 | 8.2 | 21.8 | 3.9% | +2234% | 37% | 180% |
| Median of these 10 | 27.7 | 4.2 | 16.6 | 3.5% | +12% | 17% | 19% |
; EV/Sales 2.9 vs. 4.2.
Growth vs. price
each dot a company · hover or tap for valuesELAN and VTRS and HIMS have no P/E (earnings not positive) and are left out · hover or tap a dot for values.
Elanco Animal Health Incorporated — questions
- What is Elanco Animal Health Incorporated's market cap?
- $11.3B.
- What is Elanco Animal Health Incorporated's price-to-sales ratio?
- 2.2.
Every figure on this page comes from Elanco Animal Health Incorporated's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.